Synex Medical is developing a portable MRI-based device that uses magnetic resonance spectroscopy to measure glucose and other small molecules noninvasively. The current prototype is roughly the size of a toaster; the founder aims to shrink it eventually to a palm-sized device. The system first creates a 3D image of the finger to find the best spot, then sends radio pulses to excite molecules and filters the signals to isolate a target like glucose. Synex plans to start with glucose testing and later track amino acids, lactate, ketones and other biomarkers. The company faces significant technical and regulatory hurdles, including the need for rigorous FDA clinical trials and strong competition from startups and large tech firms. Financially, Synex announced a $21.8 million Series A, bringing total capital raised to over $36 million including prior seed funding from Sam Altman. Synex Medical develops a wearable device that non-invasively measures blood metabolites such as glucose, lactate and ketones in real time using magnetic resonance technology. The technology is based on the same magnetic resonance principle used in MRI and is intended to provide data-rich insights into metabolism that affect weight, athletic performance and diabetes risk. Founded in 2017 and based in Toronto, the company plans to expand operations to Boston and grow its team. Synex raised a $6.99 million CAD ($5.25 million USD) seed round to support hiring and U.S. expansion. The product is positioned to enable continuous metabolic monitoring and to support predictive analytics approaches aimed at reducing health care costs. The offering is pitched as a painless, easy way to give users actionable insight into how diet, sleep and exercise affect their bodies.

Total raised

$27M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2024